Stock Scorer

Valion Bio, Inc. (VBIO)

Valion Bio, Inc. reported revenue of 146K USD for the quarter ending 30 September 2025, up 15.9% from 126K a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q3 '25 · ending 30 September 2025 146K +15.9%
Gross Profit Q3 '25 · ending 30 September 2025 -145K -583.3%
Operating Income Q2 '26 · ending 30 June 2026 -6.4M —
Net Income Q2 '26 · ending 30 June 2026 -7.1M —
Cost of Revenue Q3 '25 · ending 30 September 2025 291K +254.9%
Operating Cash Flow Q2 '26 · ending 30 June 2026 -5.3M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -5.3M —
Shares Outstanding Q2 '26 · ending 30 June 2026 3.4M +466.8%
EPS Q2 '26 · ending 30 June 2026 -7.72 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20242024-12-31 780K-4.5M-5.7M-5.7M
20232023-12-31 1.2M-8.2M-8.2M-8.6M
20222022-12-31 1.8M-10.1M-10.1M-8.9M
20212021-12-31 1.3M-5.6M-8.5M—

Every period

Revenue Quarterly

PeriodEndingRevenue
Q3 '252025-09-30146K
Q2 '252025-06-3086K
Q1 '252025-03-3170K
Q4 '242024-12-31180K
Q3 '242024-09-30126K
Q2 '242024-06-30140K
Q1 '242024-03-31334K
Q4 '232023-12-31357K
Q3 '232023-09-30282K
Q2 '232023-06-30161K
Q1 '232023-03-31376K
Q4 '222022-12-31408K
Q3 '222022-09-30477K
Q2 '222022-06-30528K
Q1 '222022-03-31428K
Q4 '212021-12-31389K
Q3 '212021-09-30277K
Q2 '212021-06-30268K
Q1 '212021-03-31323K

Gross Profit Quarterly

PeriodEndingGross Profit
Q3 '252025-09-30-145K
Q2 '252025-06-3054K
Q1 '252025-03-3150K
Q3 '242024-09-3044K
Q2 '242024-06-3030K
Q1 '242024-03-31167K
Q4 '232023-12-315K
Q3 '232023-09-30108K
Q2 '232023-06-3061K
Q1 '232023-03-31113K
Q4 '222022-12-3143K
Q3 '222022-09-3063K
Q2 '222022-06-30125K
Q1 '222022-03-3170K
Q4 '212021-12-31-2K
Q3 '212021-09-30-26K
Q2 '212021-06-30-33K
Q1 '212021-03-3122K

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-6.4M
Q1 '262026-03-31-5.6M
Q4 '252025-12-31-2M
Q3 '252025-09-30-2.5M
Q2 '252025-06-30-1.7M
Q1 '252025-03-31-1.4M
Q4 '242024-12-31-298K
Q3 '242024-09-30-1.4M
Q2 '242024-06-30-1.3M
Q1 '242024-03-31-1.5M
Q4 '232023-12-31-2.2M
Q3 '232023-09-30-1.8M
Q2 '232023-06-30-2.1M
Q1 '232023-03-31-2.1M
Q4 '222022-12-31-2.3M
Q3 '222022-09-30-2.6M
Q2 '222022-06-30-3M
Q1 '222022-03-31-2.2M
Q4 '212021-12-31-2.3M
Q3 '212021-09-30-1.2M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-7.1M
Q1 '262026-03-31-6.2M
Q4 '252025-12-31-2.8M
Q3 '252025-09-30-2.6M
Q2 '252025-06-30-1.9M
Q1 '252025-03-31-1.5M
Q4 '242024-12-31-1.5M
Q3 '242024-09-30-1.4M
Q2 '242024-06-30-1.3M
Q1 '242024-03-31-1.5M
Q4 '232023-12-31-2.2M
Q3 '232023-09-30-1.8M
Q2 '232023-06-30-2.1M
Q1 '232023-03-31-2.1M
Q4 '222022-12-31-2.3M
Q3 '222022-09-30-2.6M
Q2 '222022-06-30-3M
Q1 '222022-03-31-2.2M
Q4 '212021-12-31-3.7M
Q3 '212021-09-30-2.3M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q3 '252025-09-30291K
Q2 '252025-06-3032K
Q1 '252025-03-3120K
Q4 '242024-12-31419K
Q3 '242024-09-3082K
Q2 '242024-06-30110K
Q1 '242024-03-31167K
Q4 '232023-12-31352K
Q3 '232023-09-30174K
Q2 '232023-06-30100K
Q1 '232023-03-31263K
Q4 '222022-12-31365K
Q3 '222022-09-30414K
Q2 '222022-06-30403K
Q1 '222022-03-31358K
Q4 '212021-12-31391K
Q3 '212021-09-30303K
Q2 '212021-06-30301K
Q1 '212021-03-31301K

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-5.3M
Q1 '262026-03-31-5M
Q4 '252025-12-31-2.3M
Q3 '252025-09-30-2M
Q2 '252025-06-30-1.8M
Q1 '252025-03-31-889K
Q4 '242024-12-31-1.4M
Q3 '242024-09-30-1.4M
Q2 '242024-06-30-1.3M
Q1 '242024-03-31-1.7M
Q4 '232023-12-31-1.8M
Q3 '232023-09-30-1.9M
Q2 '232023-06-30-2.4M
Q1 '232023-03-31-2.4M
Q4 '222022-12-31-2.2M
Q3 '222022-09-30-2.8M
Q2 '222022-06-30-1.8M
Q1 '222022-03-31-2.2M
Q4 '212021-12-31-2.8M
Q3 '212021-09-30-1.6M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-5.3M
Q1 '262026-03-31-5M
Q4 '252025-12-31-2.3M
Q3 '252025-09-30-2M
Q2 '252025-06-30-1.8M
Q1 '252025-03-31-889K
Q4 '242024-12-31-1.4M
Q4 '232023-12-31-1.8M
Q3 '232023-09-30-1.9M
Q2 '232023-06-30-2.5M
Q1 '232023-03-31-2.5M
Q4 '222022-12-31-2.2M
Q3 '222022-09-30-2.8M
Q2 '222022-06-30-1.8M
Q1 '222022-03-31-2.2M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-303.4M
Q1 '262026-03-312.9M
Q3 '252025-09-301.3M
Q2 '252025-06-30881.3K
Q1 '252025-03-31596.4K
Q3 '242024-09-306.2M
Q2 '242024-06-30235.9K
Q1 '242024-03-3186.3K
Q3 '232023-09-301.2M
Q2 '232023-06-30296.8K
Q1 '232023-03-31201.2K
Q3 '222022-09-3096.8K
Q2 '222022-06-309.6M
Q1 '222022-03-319.7M
Q3 '212021-09-302.6M
Q2 '212021-06-302.4M
Q1 '212021-03-312.3M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-7.72
Q1 '262026-03-31-7.74
Q4 '252025-12-31-8.03
Q3 '252025-09-30-25.29
Q2 '252025-06-30-23.55
Q1 '252025-03-31-26.73
Q4 '242024-12-31-41.36
Q3 '242024-09-30-188.95
Q2 '242024-06-30-190.20
Q1 '242024-03-31-191.99
Q4 '232023-12-31-185.36
Q3 '232023-09-30-42.48
Q2 '232023-06-30-68.00
Q1 '232023-03-31-61.16
Q4 '222022-12-31-50.87
Q3 '222022-09-30-28.02
Q2 '222022-06-30-1.92
Q1 '222022-03-31-2.06
Q4 '212021-12-31-2.41